JHVEPhoto/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) on Thursday announced that its QWINT-1 and QWINT-3 Phase 3 clinical trials for once-weekly insulin efsitora alfa reached the primary endpoints against daily basal insulins, indicating a more convenient treatment regimen for adults with type 2 diabetes.